EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study

Markus Magerl iD, Guido Schiffhorst iD, Lena Fanter iD, Gerrit Müller iD, Christoph Hirche iD, Fabian Berkemeier iD, Emel Aygören iD

Allergy · 2024

DOI: 10.1111/all.15861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Markus Magerl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Fraunh…. Hauptthemen laut MEDLINE: Angioedemas, Hereditary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison.

Methods

Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data ( n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model.

Results

Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727).

Conclusion

This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryHumansTreatment OutcomeComplement C1 Inhibitor ProteinAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

C1-esterase inhibitorhereditary angioedemaindirect comparisonlanadelumablaryngeal attacks

Substanzen

lanadelumabComplement C1 Inhibitor ProteinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immun…
  • IGES Institute GmbH, Berlin, Germany.
  • Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.
  • Universitätsklinikum Frankfurt, Frankfurt, Germany.

ORCID-Profile: Markus Magerl, Guido Schiffhorst, Lena Fanter, Gerrit Müller, Christoph Hirche, Fabian Berkemeier, Emel Aygören

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Magerl, M., Schiffhorst, G., Fanter, L., Müller, G., Hirche, C., Berkemeier, F., & Aygören, E. (2024). Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study. Allergy. https://doi.org/10.1111/all.15861

Vancouver

Magerl M, Schiffhorst G, Fanter L, Müller G, Hirche C, Berkemeier F, et al. Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study. Allergy. 2024. doi:10.1111/all.15861

BibTeX
@article{Magerl2024,
  author = {Magerl, Markus and Schiffhorst, Guido and Fanter, Lena and Müller, Gerrit and Hirche, Christoph and Berkemeier, Fabian and Aygören, Emel},
  title = {Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15861}
}
Kostenlos starten →